CDT 2026 Made Salivary Diagnostics Billable. Now Dental Practices Have to Decide If They're Ready to Be Disease Screeners.

CDT 2026's introduction of D0426 crosses a threshold that a decade of salivary biomarker research never could: it transforms chairside saliva testing from a research protocol into a reimbursable clinical act. The ADA's September 2025 release of CDT 2026 framed D0426 — "Collection, Preparation, and Analysis of Saliva Sample – Point-of-Care" — as enabling precise documentation of in-office salivary analysis without external lab submission. That billing authority is the simplest part of what comes next. The harder question (one the industry hasn't squarely faced) is whether the average dental practice has the referral pathways, documentation standards, consent architecture, and liability framework to responsibly act on what those tests reveal.

What CDT 2026 Actually Did: Turning a Decade of Biomarker Research Into a Billing Line Item

D0426 didn't arrive alone. Two previously existing salivary test codes were simultaneously revised to specify their scope as laboratory-based only, creating a formal structural bifurcation between chairside and send-out salivary workflows. ADCA Online The ADA's intent is deliberate: point-of-care saliva testing now has a distinct billing identity, separate from the lab-referral model practices have used for years. CDT 2026's 60 total code changes include composite descriptor revisions and nitrous oxide documentation clarifications, but D0426 is categorically different. It signals that the ADA views chairside salivary diagnostics as a normalized clinical act, full stop.

Point-of-care testing, by definition, produces results within the same appointment window. A chairside salivary panel flagging elevated inflammatory markers or periodontal pathogens can reshape the treatment conversation before the patient leaves the chair. Dentalogic, 2026 That speed advantage is precisely what D0426 is built to document and bill.

What D0426 doesn't guarantee is payment. Northeast Delta Dental already lists the code as a denied benefit under standard plan terms. Dental Claim Support The CDT system establishes reporting standards; individual payer coverage decisions operate on a separate, slower timeline. Practices need patient-specific benefit verification before billing D0426 on any claim. The code normalizes the act of chairside salivary diagnosis. Revenue realization depends on payer adoption that will be uneven for at least the next two to three years.

What Saliva Can and Cannot Reliably Detect at the Point of Care Today

The biomarker research underpinning point-of-care salivary diagnostics has matured meaningfully. For oral squamous cell carcinoma (OSCC) detection, specific biomarker combinations show performance metrics worth taking seriously in a clinical context. A CYP27A1 plus SIAE combination achieved an AUC of 0.84, sensitivity of 0.73, and specificity of 0.80. For patients under 60, the MAOB-NAB2 pairing performed stronger: AUC of 0.91, sensitivity of 0.92, and specificity of 0.86. PMC Emerging Salivary Biomarkers for OSCC, 2025 Salivary IL-8 has demonstrated sensitivity of 0.81 for head and neck squamous cell carcinoma. Beyond oncology, myeloperoxidase (MPO) testing flags cardiovascular inflammatory risk, and salivary microRNAs show early diagnostic potential for metabolic conditions including diabetes.

The clinical constraint is substantive, though. As of late 2023, the FDA had not approved any salivary diagnostic tests for evaluating periodontal disease risk, dental caries risk, or head and neck cancer. ADA Guide to Salivary Testing, January 2025 The ADA's Living Guideline Program deferred its guidance on salivary tests to a later 2026 publication specifically because the evidence base isn't yet benchmarked against clinical gold standards at population scale. ADA News, March 2026 Research cohort sensitivity numbers and real-world diagnostic utility in a general dental patient population are not the same measurement.

Sampling variability, lack of standardized collection protocols, and insufficient large-scale validation are recurring barriers throughout the literature. MDPI Saliva as Diagnostic Tool, 2025 The point-of-care applications with the most defensible clinical footing today center on periodontal pathogen profiling and inflammatory marker monitoring. Practices deploying D0426 for caries risk stratification or periodontal disease monitoring are working in a far more validated clinical space than those positioning chairside salivary panels as general cancer detection tools.

The Referral Infrastructure Problem: Identifying a Condition Is the Easy Part

A positive or elevated salivary biomarker result triggers a clinical obligation. The obligation extends beyond documenting the result and filing it; it requires referring the patient to a qualified specialist and tracking that referral to resolution. This is where the gap between billing eligibility and practice readiness becomes acute.

Research consistently identifies EHR interoperability as the primary bottleneck in medical-dental collaboration. Without shared or interoperable health records, tracking referral outcomes across a dental-to-medical handoff is operationally fragile. Frontiers in Public Health, 2026 CMS addressed this directly in November 2025, incorporating a new oral health quality improvement activity into the Merit-Based Incentive Payment System requiring Medicare-participating physicians to implement dental referral networks and take at least one documented step toward oral health integration. ADA News, November 2025 The gap runs in both directions, and the CMS move acknowledges that dentistry's referral problem is a system-level problem.

For a solo practice without an existing physician network, a flagged MPO result or elevated cancer-associated biomarker means improvising a referral pathway in real time. DSO-affiliated practices have a structural advantage here. Dental365 has integrated SalivaScore into its clinical workflow, training its clinicians as "oral physicians" with administrative infrastructure for referral documentation at scale. Becker's Dental Review, 2025 For the independent practice adding D0426 to its fee schedule this quarter, that infrastructure doesn't exist by default.

The issue compounds at higher biomarker stakes. An elevated salivary marker associated with OSCC risk produces a flag that demands escalation. A practice generating that flag without a built escalation pathway is creating actionable clinical data in a system that isn't equipped to act on it.

Liability in the Middle: What Dentists Are Legally Responsible for When a Test Comes Back Positive

Dental malpractice law is unambiguous on this point: once a clinician has clinical reason to suspect malignancy, the standard of care requires timely referral and documentation. Failure to refer has produced substantial settlements. A New York oral cancer malpractice case resulted in a $500,000 settlement against a dentist whose failure to diagnose allowed disease to progress. Chianese & Reilly Law, 2025 The legal standard centers on what a reasonably prudent clinician would have done with the available clinical data at the time of the encounter.

CDT 2026 adds a new variable to that calculus. If a practice bills D0426 and performs a salivary panel, the result enters the clinical record permanently. A borderline or elevated result that isn't escalated or referred becomes documentary evidence of a missed obligation. The act of running the test raises the standard of care applied to that specific patient encounter.

The ADA's 2026 Living Guideline on oral cancer detection is explicit: negative adjunct test results do not rule out disease, and persistent or progressing mucosal abnormalities require biopsy or specialist referral regardless of test findings. ADA Oral Cancer Guideline, 2026 That logic extends directly to salivary diagnostics. The test informs clinical judgment; it cannot replace the obligation to escalate.

Practices introducing salivary diagnostics without updated informed consent language, documented result-escalation protocols, and staff trained on positive-result workflows are taking on liability exposure they haven't priced into their operational model.

The Revenue Case and the Risk Case: Why Practices Have to Evaluate Both Before Deploying

D0426's billing viability depends heavily on payer mix. At practices with predominantly indemnity or premium PPO patients, there's a plausible path to reimbursement as payer adoption grows, but that timeline is carrier-specific and unpredictable. At Medicaid-heavy practices, D0426 will operate as an elective, patient-pay service for the foreseeable future. The revenue case is real but unevenly distributed across practice demographics.

The patient retention and differentiation argument is more consistent across practice types. Salivary diagnostics, positioned as disease surveillance rather than a discrete billing service, change the clinical conversation meaningfully. Dental365's SalivaScore deployment frames chairside testing as tissue health monitoring, moving clinical relationships toward proactive disease management. OralDNA, 2026 That positioning generates case acceptance value for periodontal treatment plans regardless of whether the insurer covers the diagnostic code.

The risk case deserves equal weight in any deployment decision. A practice running salivary diagnostics without a referral pathway, escalation protocol, and updated consent forms is generating clinical obligations it isn't prepared to fulfill. The liability scenario is foreseeable: a practice runs a salivary panel, the result flags an elevated marker, nothing is escalated, and the patient progresses to late-stage disease. That scenario follows directly from existing case law on missed diagnoses applied to a new diagnostic instrument.

Which Practices Are Positioned to Lead This Shift, and Which Will Wait Until They're Two Years Behind

Multi-location DSOs and well-capitalized group practices will operationalize D0426 first. The ones that do it correctly will use the code as a clinical positioning tool, building referral tracking systems, updated consent forms, and standardized escalation protocols before scaling the diagnostic service. More than 60% of DSOs are already using AI-driven diagnostics and workflow automation as of 2025, per industry reporting. Overjet DSO Technology Guide, 2025 Adding salivary diagnostics to that infrastructure is an extension of existing workflows, not a new build.

Independent practices are working from a different starting point. For those smaller practices, the right sequence is clear: build the physician referral network, document the escalation protocol, update consent language, then add the diagnostic capability. Treating D0426 as a revenue line item before treating it as a clinical responsibility is the specific error to avoid.

The practices that will be two years behind aren't the ones who waited to adopt salivary diagnostics carefully. They're the ones who adopted the billing code, skipped the infrastructure, and are now managing the consequences. CDT 2026 made the billing act legitimate. It didn't make the downstream obligations any smaller.